Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free

Did Actuate Therapeutics Beat Earnings?

Actuate Therapeutics (ACTU) reported Q2 '26 revenue of $0.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Actuate Therapeutics’s job postings, web traffic, and employee business outlook. See the full ACTU stock analysis or the earnings calendar for upcoming reports.

Actuate Therapeutics Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue————————
Gross margin————————
Operating margin————————
Net income-6M-6.4M-6.3M-5.9M-5.4M-4.6M-5.6M-4.9M
Net margin————————
EPS————————

Actuate Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Actuate Therapeutics’s quarterly revenue moved from $0 to $0.

When Is Actuate Therapeutics’s Next Earnings Date?

Actuate Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the ACTU earnings calendar.

Frequently Asked Questions: Actuate Therapeutics Earnings

Actuate Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Actuate Therapeutics reported Q2 '26 revenue of $0.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the ACTU AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.